In spite of 15% lower total dose and 1 week longer overall treatment time in the radiation series of the chemo-radiation arm, an absolute survival benefit of 14% (P<0.01) was observed for the chemo-radiation arm of the study.
Localisation of maximum pain (retrosternal, left or right chest side), pain radiation (right arm, left arm, neck, back or epigastric), quality of pain (stabbing, pressure, burning or squeezing), pain aggravating and relieving factors (respiration, movements or rest), and additional symptoms (dyspnoea, nausea, vertigo, sweating) were asked.
Of the four resulting from SAEs, one death (radiotherapy arm) resulting from radiation pneumonitis was initially considered by the investigator to be unrelated to study treatment, but this was revised subsequently to pneumonitis probably related to study radiotherapy.
Patients randomised to conventional radiotherapy arm will receive radiotherapy with megavoltage radiation through conformal four-field box technique.
The Atmospheric Radiation Measurement (ARM) Data Integrator (ADI) is a framework designed to streamline the development of scientific algorithms that analyze, and models that use time-series NetCDF data.
Continuous observations of aerosol by ground-based networks allow researchers to trace long-term transitions in their characteristics (e.g., Aerosol Robotic Network (AERONET) Holben et al. 1998; US Department of Energy (DOE), atmospheric radiation measurement (ARM) Stokes and Schwartz 1994).
After a median of follow-up of 8 years, 22% of the patients who received combined modality therapy were alive, compared to 0% in the radiation alone arm at 3 years.
Sensing and controlling Acoustic Radiation Modes (ARMs) in the near-field of vibrating structures is of great interest for broadband noise reduction or enhancement, as ARMs are velocity distributions defined over a vibrating surface, that independently and optimally contribute to the acoustic power in the acoustic field.
Patients randomised to chemoradiation demonstrated improved overall survival (26 vs 0% at 3 years) and median survival (12.5 vs 9 months) compared to the radiation-alone arm.
In a recent Phase III trial in men with locally advanced prostate cancer, the rate of local regional control in the radiation-alone arm was 83% (Bolla et al, 2002).
